Aberrant promoter methylation of different DNA repair genes has a critical role in the development and progression of various cancer types, including head and neck squamous cell carcinomas (HNSCCs). A systematic analysis of known human repair genes for promoter methylation is however missing. We generated quantitative promoter methylation profiles in single CpG units of 160 human DNA repair genes in a set of DNAs isolated from fresh frozen HNSCC and normal tissues using MassARRAY technology. Ninety-eight percent of these genes contained CpG islands (CGIs) in their promoter region; thus, DNA methylation is a potential regulatory mechanism. Methylation data were obtained for 145 genes, from which 15 genes exhibited more than a 20% difference in methylation levels between tumor and normal tissues, manifested either as hypermethylation or as hypomethylation. Analyses of promoter methylation with mRNA expression identified the DNA glycosylase NEIL1 (nei endonuclease VIII-like 1) as the most prominent candidate gene. NEIL1 promoter hypermethylation was confirmed in additional fresh frozen HNSCC samples, normal mucosa, HNSCC cell lines and primary human skin keratinocytes. The investigation of laser-microdissected tissues further substantiated increased methylation levels in tumor versus matched non-tumor cells. Immunohistological analysis revealed significantly less NEIL1 protein expression in tumor tissues. 5-Aza-2 0 -deoxycytidine treatment and DNMT1 knockdown resulted in the re-expression of NEIL1 in HNSCC cell lines, which initially carried hypermethylated promoter regions. In conclusion, our results suggest that DNA methylation contributes to the downregulation of NEIL1 expression and might thus have a role in modulating the response to therapies of HNSCC.
INTRODUCTION
DNA repair has an important role in genetic instability, is involved in tumor initiation and progression and can modulate cancer therapy outcome. 1 Changes in DNA repair function were found to be induced by mutations and epigenetic mechanisms. It is now recognized that epigenetic changes such as aberrant DNA methylation could be included as one of the 'hits' in Knudson's two-hit hypothesis. Epigenetic modifications, especially DNA methylation, leading to gene silencing have been shown to be a relevant factor in the disease progression of many cancers including head and neck squamous cell carcinoma (HNSCC).
HNSCC of the oral cavity, oropharynx, hypopharynx or larynx is the sixth most common cancer by incidence worldwide, with B600 000 expected cases in 2011. 2 Despite the treatment options of surgery, radiation and chemoradiation therapy, o50% of all patients survive for 5 years, and this situation has not much improved within the last 20 years. 3 The role of genetic alterations in the development of HNSCC has been extensively studied; however, the role of many affected genes is still unknown. 4, 5 Several epigenetically silenced genes have been described in HNSCC including CDKN2A, LHX6, TCF21, CEBPA, SFRP genes, and members of the Fanconi anemia/BRCA pathway. 6 --11 Aberrant DNA methylation of DNA repair genes MGMT, MLH1 or MSH2 has been shown to have a critical role in the development and progression of HNSCC.
12 --14 A systematic screen of repair genes for promoter methylation is however missing. We therefore performed quantitative DNA methylation analyses in the promoter region of all known DNA repair and DNA repair-related genes. 15, 16 We identified novel genes showing aberrant methylation in HNSCC. The DNA glycosylase NEIL1 (nei endonuclease VIII-like 1) was among those genes showing significant hypermethylation in tumor tissues. Our results suggest that DNA methylation contributes to the regulation of NEIL1 expression and might have a role in modulating the response to therapies of HNSCC.
RESULTS

Screening of promoter methylation in HNSCC revealed aberrantly methylated target genes
Using evidence from the UCSC CpG Islands Track (NCBI build 36/hg18 human assembly) we found that 158 out of 160 investigated genes contained CpG island (CGI) in the 5 0 regulatory region offering the potential for epigenetic gene regulation as a regulatory mechanism for DNA repair genes. Two genes (POLN and RPA4) contained no CGI within 10 kb upstream or downstream of the transcription start site. The screen of promoter DNA methylation of 158 genes was performed using a set of 20 HNSCC tissues from patients and 5 normal head and neck mucosa samples from non-cancer patients. For 13 genes, methylation data could not be obtained due to problematic sequence composition of the region of interest. At the end, quantitative promoter methylation data in single CpG resolution were obtained for 145 DNA repair genes (5353 CpGs in total). Because of the low number of samples used in the screen, any statistical analysis would not be conclusive. Therefore, we decided to use a non-statistical approach based on the range of methylation values in each group. A gene was defined as aberrantly hypermethylated when the maximum methylation value of tumors was 420% higher than the maximum of normal tissues, and as aberrantly hypomethylated when the minimum value of tumors was 420% lower than the minimum value of normal tissues. The majority of screened genes (109 genes) showed methylation differences lower than 10% between normal and tumor tissues. Thirty-six genes showed methylation differences 410% (Figure 1a) . Out of these, 15 genes showed a higher than 20% difference in their DNA methylation level and were classified as aberrantly methylated. Ten of them were located on autosomes and five genes on the X chromosome.
For validation, these 15 genes were analyzed for promoter methylation in 47 tumor and 31 normal tissue samples (Table 1) . Four genes showed an increased methylation (SALL3, NEIL1, FANCB and MGMT) and three genes showed a decreased methylation in tumor samples versus controls (APEX2, TREX2, MSH4; probability values from Wilcoxon rank-sum tests under 0.05). The methylation differences of X-linked DNA repair genes in males and females were separately calculated and displayed (FANCB, APEX2 and TREX2). There was no indication that methylation levels of autosomal genes were affected by gender. Methylation levels of long interspersed nucleotide elements (LINE-1) were analyzed to obtain an estimate for global DNA methylation changes. 17, 18 Figure 1. (a) High-throughput methylation analysis of DNA repair genes. Graphical display of differentially methylated genes of 20 HNSCC samples. Each row of the heat map represents a tumor sample and each column represents a methylation difference between tumor and normal tissue. Methylation differences were estimated using the range of methylation values of each group (tumor versus normal), as described in the text. Red color indicates hypermethylation. Green color indicates hypomethylation in tumor compared with normal tissues. Gray indicates unavailable data. (b) mRNA expression of aberrantly methylated genes in HNSCC. Box-and-whisker plot of mRNA expression in a subset of HNSCC (T; n ¼ 27) compared with normal mucosa (N; n ¼ 18) as measured by qRT-PCR. Normalized expression levels were determined using HPRT1, GAPDH and ACTB as reference genes. The differences of mRNA expression between tumor and normal in NEIL1, APEX2 and MSH4 were statistically significant (Wilcoxon rank-sum test; *Po0.01; **Po0.001). Whisker indicates 10 --90% percentile. Correlation between methylation and mRNA expression was estimated by Spearman's rank correlation ( D Po0.01).
Tumor samples showed significantly lower methylation levels of LINE-1 elements compared with normal mucosa.
Correlation of mRNA expression with aberrant DNA methylation Expression analyses of the seven selected genes were performed in a subset of samples using quantitative real-time PCR (qRT-PCR). Data for FANCB were not available due to technical limitations. Expression of mRNA of genes located on X chromosome (APEX2 and TREX2) was not affected by gender as would have been expected due to X inactivation (Wilcoxon rank-sum test; P40.05; data not shown). Therefore, expression data of males and females are shown together. NEIL1, APEX2 and MSH4 showed a decreased mRNA expression in tumors (Figure 1b ). NEIL1, a bifunctional DNA glycosylase involved in base excision repair of oxidatively damaged DNA, 19 showed the most significant difference in the frequency of hypermethylated samples (62% of tumor samples showed hypermethylation in HNSCC, Po0.0001). This hypermethylation corresponded to a decrease in mRNA expression (Figure 1b ; Po 0.001; Wilcoxon rank-sum test).
Frequent DNA methylation of NEIL1 promoter in HNSCC Two isoforms of NEIL1 are annotated in the UCSC genome browser. The first isoform contains nine coding exons and codes for a protein with 390 aa (indicated here as NEIL1_1). The second isoform contains 10 coding exons and codes for a protein with 478 aa (NEIL1_2). The PCR amplicon of NEIL1, which was used for the methylation screening, was located between transcription start site and the CGI (Figure 2a) . A more detailed analysis revealed that the informative CpG units of NEIL1 cover a region of 187 bp located adjacent to the CGI, whereas other regions remained unmethylated (Supplementary Figure S2) .
For further validation, NEIL1 promoter hypermethylation was confirmed in additional fresh frozen tissue samples (total number: 135 tumor and 38 normal tissues), in HNSCC cell lines derived from primary tumors (n ¼ 34) and in primary human skin keratinocytes (n ¼ 4). The methylation level was elevated in HNSCC versus non-cancerous tissue (Po0.0001) with 71% of samples showing increased methylation (Figure 2b ). To exclude the possibility that contamination with other tissue types might affect the methylation pattern of tumor samples, six HNSCC samples were laser microdissected to enable a separate analysis of highly pure tumor and surrounding non-tumor tissue. In four out of six pairs, the tumor fraction showed at least a 20% higher methylation level than the matched non-tumor tissue. In addition, high levels of promoter methylation were observed in most of the tested HNSCC cell lines (90% frequency) but not in primary human skin keratinocytes. Overall, NEIL1 promoter hypermethylation in HNSCC tumors was consistent throughout the different samples sets used in this study.
NEIL1 downregulation in HNSCC Since we checked only mRNA expression of NEIL1_1 isoform in the screening step, another primer pair was designed in order to distinguish both isoforms ( Figure 2a ). Both NEIL1_1 and NEIL1_2 were expressed in normal tissue samples, which showed a low methylation level. This expression, however, was significantly decreased in tumor tissue (Supplementary Figure S3) . Estimates of Spearman's rank correlation revealed an inverse relationship between promoter DNA methylation and NEIL1_1 mRNA expression (r s ¼ À0.63; Po0.0001; Figure 3a ). This correlation was also observed for the NEIL1_2 isoform (Supplementary Figure S4) . NEIL1_1 expression in HNSCC cell lines was lower than in primary human skin keratinocytes, which also showed a lower NEIL1 methylation ( Figure 3b ).
We analyzed NEIL1 protein expression in normal and tumor tissues by immunohistochemistry using a monoclonal antibody recognizing the N-terminus of NEIL1. Representative staining preparations are shown in Figure 3c . Statistical results are 
Abbreviations: HNSCC, head and neck squamous cell carcinoma; LINE-1, long interspersed nucleotide elements. a Statistically significant differences (bold) between tumor and normal tissues according to the Wilcoxon rank-sum test.
b Frequency of samples with aberrant methylation is a number of tumor samples which showed higher (Hypermeth.) or lower (Hypometh.) methylation level than mean methylation level ± s.d. of normal samples. The DNA repair methylome in head and neck cancer J Chaisaingmongkol et al summarized in Table 2 . We observed less protein expression in tumor (n ¼ 8) than in normal tissue (n ¼ 5). None out of eight tumor samples and three out of five normal tissue samples showed moderate-to-strong NEIL1 expression (Fisher's exact test, Po0.05).
Promoter demethylation leads to upregulation of NEIL1 mRNA expression To confirm the functional significance of DNA methylation for mRNA expression, we investigated whether demethylation of highly methylated NEIL1 promoter regions leads to re-expression of NEIL1. A pair of HNSCC cell lines showing high and low NEIL1 methylation was selected. HNO97 showed low NEIL1 methylation (2%) and a considerable amount of NEIL1 mRNA expression. HNO223 showed a very high methylation level (77%) and low mRNA expression (Figure 4a ). Both cell lines were treated with 5-aza-2 0 -deoxycytidine (5-Aza-dC) for 72 h. A decrease of LINE-1 methylation was used as an indicator for the effect of 5-Aza-dC treatment on global methylation changes (Figure 4b ). NEIL1 methylation levels decreased with increasing concentrations of 5-Aza-dC, especially in HNO223 that initially showed high promoter methylation (from 78 to 45%; Figure 4b ). NEIL1 mRNA expression in HNO223 was induced up to 15-fold (Figure 4c ). Very minor changes of methylation and mRNA induction after 5-Aza-dC treatment were observed in HNO97, the cell line with initially low NEIL1 methylation (Figure 4c ), although its LINE-1 methylation dropped by the same extent as in HNO223 (Figure 4b) . These results indicate a specific upregulation of NEIL1 due to demethylation of the promoter region, and not due to an unspecific effect of 5-Aza-dC, for example, by DNA damage. Interestingly, only NEIL1_1 could be induced by demethylation. To further confirm NEIL1 re-expression by demethylation, a second demethylation approach was carried out by siRNA knockdown of DNMT1. HNSCC cell lines were treated with DNMT1 siRNA for 72 h, and the knockdown efficiency was proven by qRT-PCR. DNMT1 mRNA expression was reduced by 90% in both cell lines (Figure 4e) . In HNO223, which showed initially high promoter methylation, the knockdown induced a decrease of NEIL1 methylation by 18% (Figure 4d ) and a concurrent increase in NEIL1_1 mRNA expression by a factor of 9.5 ( Figure 4e) . A smaller increase in NEIL1_2 could also be observed (5.2-fold; Figure 4e ). An B2-fold induction of NEIL1_1 and NEIL1_2 expression could be observed in HNO97. Taken together, our data suggest that expression of NEIL1 might be regulated by promoter methylation affecting mainly the first isoform.
The relevance of promoter methylation for NEIL1 expression was further studied using CpGL reporter assay in 293T cells. An NEIL1 promoter construct covering the studied 5 0 region of NEIL1 was treated with SssI or remained untreated. Luciferase expression of the methylated NEIL1 promoter construct was significantly reduced compared with the unmethylated construct (Po0.01, T-test; Figure 5 ), further strengthening our hypothesis that NEIL1 promoter methylation can reduce gene expression.
The impact of NEIL1 promoter methylation on survival end points We additionally investigated the association between NEIL1 methylation and overall survival, cancer-specific survival and recurrence-free survival in a subset of HNSCC tumors with available clinical data (n ¼ 96). Patient characteristics are summarized in Supplementary Table S3 . Log-rank tests identified survival differences according to tumor localization (Supplementary Table  S4 ). Raw estimates suggested a lower recurrence risk with increased methylation of CpG unit 1 (P ¼ 0.04), but this association disappeared after adjustment by tumor localization (Supplementary Table S5 ). No association between NEIL1 methylation and survival was found in location-stratified analyses. Methylation differences among tumor locations did not reach statistical significance.
DISCUSSION
In this study, we performed a systematic screen of all known human DNA repair and repair-related genes and identified seven candidate genes that are frequently hypermethylated or hypomethylated in HNSCC. The results include MGMT hypermethylation, which has been previously described in several studies, thus adding plausibility to our screening results. 12, 13 Information about epigenetic regulation of SALL3 and FANCB in cancer is rather rare. 20, 21 MSH4 was recently shown to be hypermethylated in HNSCC. 22 No data on aberrant promoter methylation have been published so far for NEIL1, APEX2 and TREX2. Differential methylation of MLH1 and MSH2 was not observed, maybe due to our detection method or the relatively small number of samples in our screening. The screening results suggest a propensity for aberrant methylation in DNA repair genes, which are located on the X chromosome. There is currently no conceivable explanation for this observation and additional research is needed to attain further clues.
Three out of seven differentially methylated genes are hypomethylated in HNSCC (APEX2, TREX2 and MSH4). As the promoter regions of these genes are highly methylated in normal mucosa, our results suggest that a loss of methylation in cancer might activate their expression as reported for specific genes. 23, 24 This hypothesis was however not confirmed by our expression results. The correlation between promoter hypomethylation in cancer and gene re-expression seems less straightforward, and this has been similarly reported for other genes. 25 Additional regulatory mechanisms such as microRNAs or histone modifications might also result in reduced expression in tumors. The decreased expression of MSH4 and APEX2 in HNSCC did not correlate with methylation.
Among the hypermethylated genes, NEIL1 showed the strongest correlation between methylation in HNSCC and decreased gene expression. The NEIL1 gene product is involved in base excision repair of oxidatively damaged DNA. 19 Its function as a bifunctional DNA glycosylase has been studied in relative detail. 26, 27 Cell lines lacking NEIL1 were more sensitive to g-irradiation, interstrand crosslinks and bulky adducts. 28 ,29 NEIL1 knockout mice showed increased levels of DNA damage, deletions and metabolic syndrome. 30 NEIL1 and NEIL1/NTH1 double knockout mice developed pulmonary and hepatocellular tumors. 31 Genetic alterations of the NEIL1 gene in human gastric cancer lead to impaired DNA glycosylase activity or a truncated protein. 32 Furthermore, NEIL1 has been shown to interact with other DNA repair genes which have been linked to cancer. 31, 33, 34 The level of NEIL1 is greatly diminished in cells depleted for FANC proteins and Fanconi anemia cell lines. Expression of the NEIL1 protein partially reverses the hypersensitivity of Fanconi anemia cells to interstrand crosslinks. 34 However, very few data on a possible epigenetic regulation of this gene are so far available. We show here for the first time that NEIL1 is consistently hypermethylated in HNSCC tissues and HNSCC cell lines. It remains unclear why a smaller subgroup of samples does not show increased methylation levels when compared with controls. This observation is unlikely to be caused by deletions on chromosome 15 as they have not been reported so far to occur within the chromosomal region of NEIL1 in HNSCC. 4, 5 No such chromosomal aberrations have been found in 18 out of 20 (90%) of HNSCC cell lines which we used in our experiments. 35 However, it is known that tumors have heterogeneous patterns of somatic genetic and epigenetic alterations. Previously, methylation patterns in HNSCC have been associated with etiologic exposures, such as smoking and Median of methylation levels in normal tissues was 8% (range: 0 --46%; n ¼ 38); in tumor tissues was 27% (1 --80%; n ¼ 135).
The DNA repair methylome in head and neck cancer J Chaisaingmongkol et al alcohol. 36 This makes NEIL1 methylation attractive for the use as a biomarker.
We found a significant correlation between increased methylation of the upstream promoter region and a reduction in mRNA expression of NEIL1 in our tumor samples. This observation was experimentally confirmed using a collection of HNSCC cell lines. Since NEIL1 has been shown to be activated by acute oxidative stress 37 and downregulated probably by the long-term exposure to reactive oxygen species in HCV-infected liver cells, 38 it is possible that methylation of NEIL1 promoter region controls the gene expression under these conditions. In addition, major risk factors of HNSCC such as the chronic consumption of tobacco smoke and alcohol can induce a prolonged exposure to reactive oxygen species, 39, 40 which might cause epigenetic changes, such as methylation, affecting NEIL1 expression either directly or indirectly. Furthermore, it was also shown that HNSCC risk factors (drinking, smoking and HPV) are associated with epigenetic inactivation of genes, such as the SFRP genes.
11
Future experiments will be necessary to further elucidate the role of epigenetic regulation of NEIL1 expression in HNSCC and to verify whether it is a cause or consequence of tumorigenesis. DNA methylation changes might occur early in carcinogenesis and could therefore be used as an early indicator or biomarker in clinical studies. With respect to methylation changes, one might speculate that the glycosylase activity of NEIL1, in addition to thymine-DNA glycosylase (TDG), might be implicated in the teneleven translocation (TET)-mediated and base excision repair (BER)-coupled demethylation pathways which involve oxidized products of 5-mC such as 5-hydroxymethylcytosine or 5-carboxylcytosine. 41 An impaired demethylating activity could then contribute to increased methylation in tumors.
Epigenetic silencing of DNA repair genes is thought to increase genetic instability and thus promote carcinogenesis. 42 Once the tumor has developed, decreased DNA repair gene expression can however be beneficial to the patients by increasing the sensitivity of the tumor cells to DNA-damaging therapies, as shown for MGMT hypermethylation in glioblastoma. 43 In our study, patients with high NEIL1 methylation showed a significantly higher recurrence-free survival but this was not apparent after stratification by tumor localization. The statistical power of our study cohort might however be too small for a stratified analysis. As 490% of our patients received a DNA damageinducing radiotherapy and/or chemotherapy post surgery (Supplementary Table S3 ), NEIL1 deficiency might nevertheless have the suggested positive effect in patient survival due to an increased sensitivity of the tumor cells to DNA-damaging chemotherapy or radiotherapy. For possible clinical implications, comprehensive studies with more homogenous cohorts and larger patient numbers are warranted. In any case, our novel data on aberrant promoter methylation of NEIL1 will stimulate such studies and thus open the possibility to improve HNSCC diagnosis and treatment. Supplementary  Table S6 .
Clinical information and follow-up data were analyzed by reviewing the medical records, radiographic images, by telephone or written correspondence and by review of death certificate. Mean follow-up time was 6.9 years (±3.9 years). Patients were followed from date of first diagnosis to the end of study (30 June 2010) , whereas dead patients were censored. All patients were chemotherapy and radiotherapy naive at the time of surgery.
Histological evaluation of all tissue samples was performed by a single pathologist. A subset of frozen samples was cut into 18 mm thick sections using a cryostat (Leica CM1850; Leica Microsystems, Wetzlar, Germany) and was processed by laser microdissection and pressure catapulting using a Microbeam LMPC System (Carl Zeiss MicroImaging, Jena, Germany) as described. 44 DNA was isolated using the Puregene Tissue Core Kit B (Qiagen, Hilden, Germany) according to manufacturer's instructions.
HNSCC cell lines 45 were cultured routinely in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (PAA Laboratorie, Cö lbe, Germany) and 1% penicillin/streptomycin (Sigma, St Louis, MO, USA) in an atmosphere containing 5% CO 2 . 293T cell line was cultured in the same medium without antibiotics.
Treatment of cell lines with 5-Aza-dC and siRNA HNSCC cell lines HNO97 and HNO223 were seeded in 6-well plates (1.5 Â 10 5 cells/well) containing 2 ml culture medium. Cells were treated with 5-Aza-dC dissolved in phosphate-buffered saline (5-Aza-dC; Sigma) at 0.5, 1.0 and 2.0 mM for 72 h by adding freshly prepared 5-Aza-dC in culture medium and changed every 24 h. For transient transfection with siRNA, cells were seeded as described. In all, 20 nM DNMT1 Dharmacon ON-TARGETplus SMARTpool and 2.4 ml DharmaFECT Reagent (Thermo Fisher Scientific, Lafayette, CO, USA) were prepared and added per well. Cells treated with only DharmaFECT Reagent served as a negative control. Knockdown efficiency was confirmed by qRT-PCR.
DNA and RNA isolation DNA from frozen tissue samples was isolated using DNeasy Blood and Tissue Kit (Qiagen). Total RNA from tissue samples was isolated using Trizol (Invitrogen, Karlsruhe, Germany). DNA and RNA from cell lines were isolated using AllPrep DNA/RNA Mini Kit (Qiagen).
Bisulfite conversion, primer design strategy and methylation analysis Genomic DNA was converted by bisulfite treatment using EZ DNA methylation kit (Zymo Research, Orange, CA, USA). After bisulfite conversion and PCR amplification of the DNA region of interest, MassARRAY technology (Sequenom, San Diego, CA, USA) was used to quantify the methylation status of a specific promoter region in set of 20 HNSCCs and 5 normal tissues samples as described. 46 The list of human DNA repair genes is based on a compilation by Wood et al., 15, 16 which we supplemented with 10 additional genes (Supplementary Table S1 ). PCR primers were designed to cover a region located near the transcription start site and associated with the CGI (Supplementary Figure S1) . To normalize for PCR induced biases, a 6-point methylation standard was included in the assay to generate a standard curve and used for data correction. The resulting percent methylation values are displayed as an average of all CpG units within an amplicon. Informative CpG units are defined as the CpG units depicting the strongest methylation differences between normal and tumor tissues. A smaller PCR amplicon of NEIL1 (187 bp) located within the informative region was used to characterize methylation levels in laser-microdissected tissues. Display of methylation results as heat maps and unsupervised clustering was performed using the Multiple Experimental Viewer software (http://www.tm4.org/mev.html).
Reverse transcription and qRT--PCR
The total RNA (500 ng --1 mg) was treated with DNaseI (Fermentas, St LeonRot, Germany) followed by cDNA synthesis using SuperScript III reverse transcriptase (Invitrogen) and random hexamers. Primers and PCR conditions are shown in Supplementary Table S2 . Quantitative mRNA expression analysis was performed using the Absolute QPCR SYBR Green Mix (ABgene, Epsom, UK) on a LightCycler 480 (Roche Diagnostics, Mannheim, Germany) as described. 47 Normalized expression ratios were determined for each sample using HPRT1, GAPDH and ACTB as reference genes. Stratagene QPCR Human Reference Total RNA (Agilent Technologies, Santa Clara, CA, USA) was used as a calibrator for calibratornormalized relative quantification.
Immunohistochemistry
Immunohistochemical staining was performed using a mouse monoclonal antibody recognizing the N-terminus of NEIL1 (sc-271167; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a concentration of 10 mg/ml. Specificity of primary antibodies was ensured using an irrelevant control antibody. Incubation with primary and secondary antibodies and detection with Vectastain ELITE ABC Kit (Vector Laboratories, Burlingame, CA, USA) was carried out as described. 45 An amplification step was performed with the Tyramide Signal Amplification kit (NEL700; Perkin-Elmer, Rodgau, Germany) according to manufacturer's instructions.
Luciferase reporter assay NEIL1 promoter construct covering the studied 5 0 region was cloned directly into the CpG-free pCpGL vector and SssI methylated in vitro or left unmethylated. 48 The 293T cells (3000 cells/well) were transiently transfected in 384-multiwell plates using 0.2 ml TransIT-LT1 Transfection Reagent (Mirus Bio, Madison, WI, USA) and 40 ng of reporter plasmid and 10 ng of Renilla vector (Promega, Mannheim, Germany) according to manufacturer 0 s instructions. After 48 h, cells were harvested, and cell lysates assayed for firefly and Renilla luciferase activity using the dual Figure 5 . DNA methylation reduced NEIL1 promoter activity. Luciferase CpG-free pCpGL vector constructs contained NEIL1 5 0 region from methylation study were M.SssI methylated or left unmethylated and transfected into 293T cells. The reporter activity was studied 48 h after transfection. Relative luciferase activity was determined by normalizing firefly luciferase against Renilla luciferase activity. Empty vectors were used to normalize the background noise. Error bars indicate s.e.m. of three independent experiments. Luciferase expression of methylated version of NEIL1 promoter construct was reduced comparing with unmethylated construct (T-test; **Po0.01).
luciferase reporter assay system (Promega) on a SPECTRAmax 250 spectrophotometer (GMI Inc., Cold Spring, NY, USA). Firefly luciferase was normalized against Renilla luciferase activity. Empty vectors were used to normalize the background noise.
Statistical analysis
Percent methylation values were compared among groups using the nonparametric Wilcoxon rank-sum test. The Wilcoxon matched pairs test was used to compare matched tumor and normal microdissected tissue samples. Correlations between methylation and mRNA expression were assessed by the non-parametric Spearman 0 s rank correlation coefficient (r s ). Fisher's exact test was chosen to examine the association between tissue type and protein overexpression. Survival differences between groups of patients were explored by log-rank tests and subsequent multivariate Cox regression models. GraphPad Prism (GraphPad Software Inc, La Jolla, CA, USA) was applied for the analysis.
